scholarly article | Q13442814 |
P50 | author | James Rutka | Q17156655 |
Tobey J MacDonald | Q99550976 | ||
Livia Garzia | Q114421153 | ||
Adrian M Dubuc | Q114529448 | ||
Timothy E Van Meter | Q114529465 | ||
Patryk Skowron | Q114726875 | ||
Caitlin Hoffman | Q114726876 | ||
Benjamin Haibe-Kains | Q38639014 | ||
Stefan M. Pfister | Q39183179 | ||
Vijay Ramaswamy | Q43153342 | ||
Marc Remke | Q43153350 | ||
Stephen C Mack | Q55459128 | ||
Xin Wang | Q55459131 | ||
Deena M. A. Gendoo | Q61312308 | ||
Eric Bouffet | Q64584887 | ||
Cynthia Hawkins | Q64584929 | ||
Betty Luu | Q87124261 | ||
Charles G Eberhart | Q87148391 | ||
David Lyden | Q87823035 | ||
David Zagzag | Q88011784 | ||
Michael D. Taylor | Q88072573 | ||
Andrey Korshunov | Q89166780 | ||
Yoon-Jae Cho | Q90317000 | ||
Paul A Northcott | Q91826566 | ||
P2093 | author name string | Borja López | |
Xiaochong Wu | |||
Xiao-Nan Li | |||
John Peacock | |||
Florence Cavalli | |||
P2860 | cites work | Molecular subgroups of medulloblastoma: the current consensus | Q24615271 |
Summaries of Affymetrix GeneChip probe level data | Q27860888 | ||
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome | Q28298987 | ||
Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification | Q28299667 | ||
Subtypes of medulloblastoma have distinct developmental origins | Q28300616 | ||
Diagnosis of multiple cancer types by shrunken centroids of gene expression | Q29615528 | ||
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma | Q29615604 | ||
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. | Q30447832 | ||
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features | Q33366431 | ||
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 | ||
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma | Q34215755 | ||
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma | Q34391844 | ||
An animal model of MYC-driven medulloblastoma | Q35774418 | ||
Clonal selection drives genetic divergence of metastatic medulloblastoma | Q35784926 | ||
Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples | Q35837393 | ||
Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study | Q36025964 | ||
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. | Q36673354 | ||
Medulloblastoma comprises four distinct molecular variants | Q36920479 | ||
High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031) | Q37066730 | ||
Metagenes and molecular pattern discovery using matrix factorization | Q37356699 | ||
Medulloblastomics: the end of the beginning | Q37469904 | ||
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis | Q37636027 | ||
FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. | Q37971394 | ||
Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma. | Q38120467 | ||
Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing | Q38993103 | ||
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations | Q40339027 | ||
A mouse model of the most aggressive subgroup of human medulloblastoma | Q41484437 | ||
Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays | Q43153279 | ||
Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma | Q46201996 | ||
Adult medulloblastoma comprises three major molecular variants. | Q55463035 | ||
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. | Q55469539 | ||
P4510 | describes a project that uses | limma | Q112236343 |
P433 | issue | 3 | |
P921 | main subject | medulloblastoma | Q1333608 |
P304 | page(s) | 449-457 | |
P577 | publication date | 2015-01-21 | |
P1433 | published in | Acta Neuropathologica | Q343168 |
P1476 | title | Medulloblastoma subgroups remain stable across primary and metastatic compartments | |
P478 | volume | 129 |
Q39346476 | "miR miR on the wall, who's the most malignant medulloblastoma miR of them all?" |
Q50422142 | A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. |
Q47851564 | ATOH1 Promotes Leptomeningeal Dissemination and Metastasis of Sonic Hedgehog Subgroup Medulloblastomas. |
Q41694115 | Added value of diffusion weighted imaging in pediatric central nervous system embryonal tumors surveillance |
Q48116800 | Advances in Genomics Explain Medulloblastoma Behavior at the Bedside. |
Q57805008 | BMI1 is a therapeutic target in recurrent medulloblastoma |
Q35710253 | Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup |
Q43056671 | Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas |
Q47282131 | Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. |
Q37073617 | Divergent clonal selection dominates medulloblastoma at recurrence |
Q33572502 | Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation. |
Q38652681 | Evolving molecular era of childhood medulloblastoma: time to revisit therapy |
Q36142459 | Genetic and molecular alterations across medulloblastoma subgroups |
Q53622562 | Histological subtype of medulloblastoma frequently changes upon recurrence. |
Q47816782 | Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. |
Q94527860 | Immunotherapy for Medulloblastoma: Current Perspectives |
Q33903199 | Investigation of brain tissue infiltration by medulloblastoma cells in an ex vivo model |
Q55452816 | MRI features as a helpful tool to predict the molecular subgroups of medulloblastoma: state of the art. |
Q86064194 | Medulloblastoma |
Q54954567 | Medulloblastoma in the Molecular Era. |
Q38954656 | Medulloblastoma initiation and spread: Where neurodevelopment, microenvironment and cancer cross pathways |
Q39225738 | Medulloblastoma: Molecular Classification-Based Personal Therapeutics |
Q38791824 | Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm |
Q39446793 | Medulloblastoma: experimental models and reality |
Q39134342 | Modern management of medulloblastoma: Molecular classification, outcomes, and the role of surgery |
Q37573700 | Molecular Classification of Medulloblastoma |
Q92865416 | Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches |
Q36716785 | Mutations in chromatin machinery and pediatric high-grade glioma |
Q92705351 | Preclinical Models of Craniospinal Irradiation for Medulloblastoma |
Q55403358 | Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression. |
Q37250411 | Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study |
Q88993176 | Rethinking medulloblastoma from a targeted therapeutics perspective |
Q91780113 | Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience |
Q41860267 | Silencing of Urothelial Carcinoma Associated 1 Inhibits the Proliferation and Migration of Medulloblastoma Cells |
Q34552042 | Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas |
Q98784812 | Wnt activation as a therapeutic strategy in medulloblastoma |